Which Patients With Hepatitis B Should We Be Treating?

CCO Infectious Disease Podcast

English - November 29, 2023 19:58 - 20 minutes - 18.9 MB
Courses Education Science Life Sciences hiv covid-19 cme hepatitis b hbv id medical education coronavirus hepatitis c hcv Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: A Hidden Annual Epidemic: The Burden of RSV in Adults

Next Episode: Role of Quantitative HBsAg Testing in Clinical Practice for People With CHB

Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?

To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:

Guideline-based treatment recommendations and their limitationsData describing the relationship between viral suppression and HBV DNA integrationMore expansive indications for HBV treatment based on virologic considerations

Presenters:

Ira M. Jacobson, MD
Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at
Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to the full program: https://bit.ly/3R1PMi4

Link to the slides: https://bit.ly/3N5Fpsm